Scilex Announces Production Increase, Product Availability, and The Brand for ELYXYB | SRNE Message Board Posts


Sorrento Therapeutics, Inc.

  SRNE website

SRNE   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  1940 of 2010  at  11/21/2023 1:17:07 PM  by

put_lipstick_on_this_pig


Scilex Announces Production Increase, Product Availability, and The Brand for ELYXYB

https://finance.yahoo.com/news/scilex-holding-company-announces-production-140000128.html 

 
Scilex Holding Company Announces Production Increase, Product Availability, and The Brand Marketed and Distributed Under Scilex Pharmaceuticals, Inc. for ELYXYB®
 

PALO ALTO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the increase of ELYXYB® (celecoxib oral solution) manufacturing to meet its rising demand for ELYXYB® and increased stocking needs in its distribution center. Scilex has met another significant corporate objective and produced our first commercial batch with Scilex labeled ELYXYB which will enable the Company to meet the growing demands of future customers seeking a rapid onset pain management regimen for the acute treatment of migraine.

We believe ELYXYB is the first and only ready to use oral solution designed to deliver fast and long-lasting migraine relief with the proven safety of COX-2 selectivity that is FDA-approved for the acute treatment of migraine, with or without aura, in adults.1 ELYXYB® was studied in two randomized, double-blind trials of 1,253 patients with episodic migraine (with or without aura)2. ELYXYB® treated patients demonstrated pain relief in as little as 15 minutes and significant pain relief compared to placebo within 45 minutes in nearly 50% of patients2. Approximately 36% of patients were pain free at two hours1. The U.S. migraine drug market size is estimated to be $4.1 billion in 2022.3

“We are very excited about the potential of ELYXYB® since the launch of the product in April 2023. This is a highly complementary commercial asset that allows us to provide physicians with another tool in their pain management armamentarium to treat migraines earlier in the patient journey as we continue to work towards redefining the role of opioids as a last resort rescue medication,” said Jaisim Shah, Chief Executive Officer and President of Scilex.

For more information on ELYXYB, including Full Prescribing Information, visit ELYXYB.com.



     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 1  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board




Financial Market Data provided by
.
Loading...